Clinical trials: Monoclonal Gammopathy
Monoclonal Gammopathy of Unknown Significance
Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)
This is a study to investigate the functional consequences of paraprotein production in MGUS (Monoclonal Gammopathy of Unknown Significance).
- Trial name
- NCT02933021
- Testing
- Blood sample taken, Answering a lifestyle questionnaire, Follow-up phone call from researcher (two years after first visit)
- Where
- 9 sites in United Kingdom
- Volunteers
- 664 people
- Sponsor
- RxCelerate Ltd
Monoclonal Gammopathy
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple…
- Trial name
- NCT04614558
- Testing
- Isatuximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Monoclonal Gammopathy of Undetermined Significance, Plasma Cell Myeloma
Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma
This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM).
- Trial name
- NCT03119883
- Testing
- 5-Carbon C 13-labeled Glutamine, Biospecimen Collection, Uniformly-labeled [13C]glucose
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Monoclonal Gammopathy of Undetermined Significance, Myeloma Multiple
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS).
- Trial name
- GAMY (NCT06559033)
- Testing
- Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
- Where
- 2 sites in France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004232
- Testing
- filgrastim, cyclosporine, methylprednisolone
- Where
- United States
- Sponsor
- Northwestern University
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Studying Fentanyl in Patients With Cancer
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00899951
- Testing
- fentanyl citrate, pharmacological study
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma, Smoldering Multiple Myeloma
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- TRANSFORMM (NCT05361694)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Miami
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
The purpose of this study is to determine if siltuximab has an effect on the heart function measured by ECG recordings and more specifically to determine if siltuximab has an effect on the QT interval in patients with Monoclonal…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT01219010
- Testing
- Siltuximab
- Where
- 8 sites in United States, Belgium and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade
- Trial name
- NCT02269592
- Where
- 7 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gammopathy, Monoclonal
Monoclonal Gammopathy With Clinical Significance in Patients With and Without Haematological Malignancies in Finistère Between 2012 and 2017 (GammaClinik)
Clinical symptoms associated with monoclonal gammapathy have been primarily studied in hematological malignancy and rarely in MGUS and hemopathy.
- Trial name
- GammaClinik (NCT06559579)
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Brest
Cervical Cancer, Chronic Myeloproliferative Disorders
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications.
- Conditions
- Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00006083
- Testing
- Fragmin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Monoclonal Gammopathy of Uncertain Significance, Smoldering Myeloma
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
A prospective, pilot study to assess the impact of a 12-month multi-focal lifestyle intervention on myeloma-relevant biomarkers in patients with MGUS or SM.
- Trial name
- NCT06987708
- Testing
- The Multimodal Lifestyle Intervention
- Volunteers
- 67 people
- Sponsor
- Hackensack Meridian Health
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic
Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Screening to Improve Survival in AL Amyloidosis
The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS.
- Trial name
- NCT04615572
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tufts Medical Center
Multiple Myeloma
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding…
- Trial name
- NCT01548573
- Testing
- Dexamethasone, Tandem autologous stem cell transplant, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Iowa
Monoclonal Gammopathies, Overweight
Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood.
- Conditions
- Monoclonal Gammopathies, Overweight, Obesity
- Trial name
- NCT02920190
- Testing
- Liraglutide
- Sponsor
- University of Miami
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00424242
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University